Medical Marijuana Uses
Last September, the American Nurses Association (ANA) recognized cannabis nursing as a specialty nursing practice. Rachel Parmelee, MSN, RN, and American Cannabis Nurse Association (ACNP) president, told Becker’s Hosptial Review in 2023 that the recognition highlights the value of cannabis nurses.
“Such changes enable patients to benefit from the legal and safe use of cannabinoids for disease treatment and symptom management,” Parmelee said. “Cannabis nurses lead in characterizing the urgency and efficacy of clinical research and regulatory reform associated with the use of cannabinoids.”
A recent study on the use of medical cannabis among Appalachian adults found that “health and well-being improved significantly” among those who added the drug to their treatment plans.
“Patients should feel comfortable discussing medical cannabis with their providers,” the authors stated. “Increased provider knowledge about medical cannabis use and benefits may increase their willingness to provide access for patients managing chronic conditions in Virginia’s Appalachian region.”
Other studies and research conducted over the past decade have produced similar results.
Positions on Medical Marijuana
A majority of the NP students surveyed for “The Nurse Practitioner” study believe medical marijuana should be legalized nationwide.
The ANA has supported safe access to “therapeutic marijuana and related cannabinoids” for more than two decades and reiterated its support in a 2021 position statement.
“Marijuana and its derivatives continue to be used to alleviate disease-related symptoms and side effects,” ANA stated. “The findings of anecdotal and controlled studies regarding the efficacy for patient use are mixed. Current federal regulations impede the research necessary to evaluate and determine the therapeutic use of marijuana and related cannabinoids … The goal is to develop an evidence-based approach to its use in the treatment of disease and symptom management.”
RELATED COURSE: Cannabinoid Hyperemesis Syndrome
However, support is not widespread. A “Missouri Medicine” commentary cites lack of evidence for therapeutic benefits, varying regulatory standards, and “off-label” use in its position against legalization of the drug. The American Psychiatric Association in 2019 opposed cannabis as medicine and in 2022 urged authorities “to measure and monitor the health and safety consequences of policies enacted by states that legalize the cultivation, distribution, and possession of cannabis and to fund relevant research.”
Last August, the U.S. Department of Health and Human Services proposed reclassifying marijuana from Schedule I to Schedule III under the Controlled Substances Act and the recommendation was made in January.
The Drug Enforcement Agency (DEA), in April, agreed to reclassify the substance, according to Associated Press reports, but a hearing won’t be held until December.
![Medical marijuana](https://nursingcecentral.com/wp-content/uploads/2024/09/Medical-marijuana-3.png)